Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Acute myeloid leukaemia in older or unfit patients, drawn from the whole corpus: 14 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
How long venetoclax needs to be given, and whether MRD-negative patients can stop.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Whether fit older patients do better with venetoclax-azacitidine than with intensive chemotherapy.
Infections and cytopenias that keep older patients in hospital during a treatment meant to be gentle.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
OS 24.
A milestone in how this cancer is treated.
Venetoclax + azacitidine full approval in unfit AML (VIALE-A)
Median overall survival 24.
OS 14.